CJ Warfarin

docx

School

Collin County Community College District *

*We aren’t endorsed by this school

Course

2430

Subject

Medicine

Date

Feb 20, 2024

Type

docx

Pages

2

Uploaded by SargentOtter8964

Report
Part 2 Patient-Specific Information DRUG Time Due : 1600 Dose : 2.5 mg Frequency : daily Route : PO Administration Instructions (specific to route ): administer same time each day; take missed dose ASAP on same day, do not double dose to make up for missed dose REASON What is this medication's goal/expected outcome (therapeutic effect )? Prevention of thromboembolic events; prolonged PT/INR without signs of hemorrhage What evidence from the patient’s chart supports the need for this medication? (i.e., vitals signs, assessment, lab data, medical history, etc.). Pt is short of breath and fatigued, so little activity is being done, which may lead to venous stasis and venous thrombosis SAFETY Is this a home medication? If Y is the dose the same ? New Is the ordered dose safe (according to the safe/usual dose range )? Yes What labs should be assessed prior to administration? Include lab name and client’s lab results (even if normal ). Monitor PT/INR (no labs) Is a dose adjustment required based on the client’s lab results ? No Based on your client’s other medications, are there any drug-to-drug interactions ? Spironolactone, amiodarone, furosemide Does your client have any of the known contraindications, black box warnings, or adverse effects associated with this medication? (Support with evidence) If Y, how will you manage these risks ? Nausea, hypertension- watch these in pt to make sure they do not worsen after administration Is the drug safe to administer? Y/N and Why ? ( Support with evidence) yes- safe dose, right indication, pt is prone to VTE; no serious side effects (med can still be given with these s/e) EVALUATION Did this medication achieve the desired outcome (provide evidence)? What labs/vital/assessment need to continue to be monitored after the drug is administered? PT/INR Part 1 Drug-Specific Information Name(Generic/Brand) Warfarin/Jantoven Class (Pharm/Therapeutic) P: coumarin/Vitamin K antagonist T: anticoagulant Mechanism of Action Inhibit vitamin-K dependent activation of clotting factors II, VII, IX, and X, formed in the liver; inhibits anticoagulant proteins C and S Onset & Peak PO- O: 36-72 hr P: 5-7 days Indications Prophylaxis and treatment of venous thrombowmbolic disorders (DVT/PE) and embolic complications from afib or cardiac valve replacement; reduce risk of systemic embolism after MI Drug Library safe/usual dose range 2-5 mg/day (2-4 days); adjust daily dose by INR levels Drug-to-Drug Interactions Acetaminophen (inc bleeding); allopurinol, amiodarone, beta blockers, furosemide, metronidazole, NSAIDs, salicylates, SSRIs, thyroid drugs (increase anticoagulant effect); barbiturates, carbamazepine, spironolactone, vitamin K, haloperidol (reduce PT/INR- reduce anticoag effect); oral antidiabetic (increase hypoglycemic response) Most Common & Serious Adverse Effects Vasculitis, abdominal pain, N/V/D, hemorrhage, hepatitis, alopecia, pruritis, dermal necrosis, chills, anaphylactic reactions Contraindications Black Box Warnings Hypersensiticity; active bleeding (GI, GU, or respiratory tract); aneurysm; dissecting aorta; cerebrovascular hemmorahe, severe HTN, pericarditis; recent surgery with large open areas; risk of nonadherence (alcoholism/psychosis); kidney dz pt; Patient Education Teach measures to prevent bleeding; avoid OTC products with aspirin/salicylates; avoid activities that may result in traumatic injury; avoid extra intake of vitamin K (decrease anticoagulant effects; consistent intake of vitamin K); inform all HCP about taking warfarin; report serious illness (severe diarrhea, infxn, fever); report unusual bleeding
Your preview ends here
Eager to read complete document? Join bartleby learn and gain access to the full version
  • Access to all documents
  • Unlimited textbook solutions
  • 24/7 expert homework help